Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools.

The pharmacogenomics journal - 1 Sept 2018

Bousman Chad A, Dunlop Boadie W

Abstract excerpt

The degree of agreement between four commercial pharmacogenetic-based decision support tools (DSTs) was examined in five outpatients with major depressive disorder and at least two previous antidepressant failures. Comparisons were made across seven pharmacokinetic (CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, and UGT2B15) and seven pharmacodynamic (BDNF, COMT, HLA-A, HTR2A, HTR2C, OPRM1, and SLC6A4) genes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents
Share to Antipsychotic Agents
Share to Cross-Sectional Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Depressive Disorder, Major

Share to DST gene

Share to Genotype

Share to Pharmacogenetics

Share to Phenotype

Source

Identifiers

PMID: 29795409
DOI: 10.1038/s41397-018-0027-3

Genes

BDNF
COMT
DST
OPRM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools.PMID 29795409Read ↗

Variability Between Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guidelines and a Commercial Pharmacogenetics Laboratory in Genotype to Phenotype Interpretations For Patients Utilizing PsychotropicsSemantic proximity Read ↗

Antidepressant prescribing in the precision medicine era: a prescriber’s primer on pharmacogenetic toolsSemantic proximity Read ↗

Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.Semantic proximity Read ↗

Acceptance of recommendations by a pharmacogenetics clinic.Semantic proximity Read ↗

Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients.Semantic proximity Read ↗

A Framework to Quantify Disparities in Pharmacogenomic Treatment Concordance and Drug Response OutcomesSemantic proximity Read ↗

A Framework to Quantify Disparities in Pharmacogenomic Treatment Concordance and Drug Response Outcomes.Semantic proximity Read ↗

Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics.Semantic proximity Read ↗

CYP2D6 and CYP2C19 Variant Coverage of Commercial Antidepressant Pharmacogenomic Testing Panels Available in Victoria, AustraliaSemantic proximity Read ↗

Design and Early Implementation Successes and Challenges of a Pharmacogenetics Consult ClinicSemantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 updateSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.